Real-world evidence on the CamAPS FX hybrid closed-loop system in people living with type 1 diabetes

Abstract

Background: We analysed real-world data to evaluate the performance of the CamAPS FX hybrid closed-loop system I people living with type 1 diabetes. Methods: Users from 19 countries across different age groups who used the system between January 1, 2024, and December 31, 2024, and who had ≥60 days of continuous glucose monitor data with ≥30% of closed-loop usage were included in the current analysis (N=35,714). Results: Time in target glucose range (3.9–10 mmol/l) was median (IQR) 69.6% (61.3–77.2) for all users and varied across the different age groups from 62.5% (53.4–71.2) for young adult users aged 18–22 years old to 76.1% (68.9–82.4) for users aged ≥65 years. Median (IQR) time spent in hypoglycaemia (<3.9 mmol/l) was 2.5% (1.4–3.9) overall, and was <4% across all age groups. Mean glucose and glucose management indicator overall were 8.7±1.2 mmol/l and 7.1±0.5% (53.6±5.8 mmol/mol), respectively. Median (IQR) time in closed-loop was high at 95.7% [92.9, 97.3]. Conclusions: This retrospective observational analysis of real-world data demonstrates the performance of the CamAPS FX hybrid closed-loop system with outcomes comparable to those reported from previous randomised controlled studies.